Schizophrenia Drugs Market cover

Schizophrenia Drugs Market by Therapeutic Classes (Second-generation Antipsychotics [Risperdal, Invega, Zyprexa, Geodon, Seroquel, Latuda, Aristada, Fanapt, Saphris, and Vraylar], Third-generation Antipsychotics [Abilify], and Others [First-generation Antipsychotics and Generics]), Treatments (Oral Antipsychotics and Injectable Antipsychotics), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028.

  • Report ID: CG-2199
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 3
  • No. Of Pages: 194
  • Format:
  • Pub. Date: Upcoming
  • Share:

The schizophrenia drugs market size is estimated to expand at a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the prevailing number of patients, improved healthcare services, and rising awareness among the population.

Schizophrenia Drugs Market summary

Schizophrenia is a type of mental disorder which is characterized by abnormality in interpretation of reality by the patient. The common symptoms are delusions, hallucinations, and highly disorientated thinking, which result to mismanagement of daily functioning. Men and women are equally affect by the schizophrenia; however, some reports suggest that men are more diagnosed with the disease. The mortality rate of the disease is high due to the high probability of severe heart diseases or diabetes with patient associated with schizophrenia. The symptoms appear in early stages of adulthood where in case of males, the symptoms begin in the early 20s while in females it appears in early 30s or late 20s.

As per the World Health Organization (WHO) 2019 statistics, schizophrenia had affected more than 20 million people globally and the number was likely to increase in the near future due to rising geriatric population worldwide. As per World Ageing 2019, there were about 700 million people with age 65 years or above globally. This count is expected to become twice to 1.5 billion by 2050. The geriatric population are more at risk to develop schizophrenia. Furthermore, the National Institute of Mental Health in collaboration with the American Psychiatric Association had predicted that risk of a person to develop schizophrenia during their lifespan is to be 0.3% to 0.7%. The COVID-19 pandemic had an intense effect on mental health of the population and many studies reported that the already existent health conditions in patient with schizophrenia can lead to severe COVID-19 symptoms. These factors proved to bolster the market growth during the pandemic outbreak. The pandemic created awareness among a large number of the global population to look after their health conditions and also pushed the government to take initiatives for better healthcare facilities.

Market Trends, Drivers, Restraints, and Opportunities

  • High prevalence of the disease in the world along with initiatives by the government organizations to create awareness about the disorder is a key driving force of the market.
  • Increasing new developments in the technology and rising drug developments for the treatment is expected to push the market growth in the coming years.
  • Rising personal healthcare expenditure, inclining economic growth, and growing chronic ailments are other key factors for market growth in the near future.
  • Low awareness and inadequate availability of skilled professionals in some developing and underdeveloped nations are hindering the growth of the market during the forecast period.
  • Strict regulatory guidelines for the approval and regulation of the new products is a key restraint projected to hinder the market growth.

Scope of the Report

The report on the global schizophrenia drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Schizophrenia Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Therapeutic Classes (Second-generation Antipsychotics [Risperdal, Invega, Zyprexa, Geodon, Seroquel, Latuda, Aristada, Fanapt, Saphris, and Vraylar], Third-generation Antipsychotics [Abilify], and Others [First-generation Antipsychotics and Generics]) and Treatments (Oral Antipsychotics and Injectable Antipsychotics)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Johnson & Johnson; Bristol-Myers Squibb and Company/Otsuka Pharmaceuticals; AstraZeneca; Eli Lilly; Alkermes; Sumitomo Dainippon Pharma; Pfizer; Vanda Pharmaceuticals; and Allergan/Geodon Ritcher.

Market Segment Insights

Second-generation antipsychotics segment is expected to grow at a considerable pace

Based on therapeutic classes, the global schizophrenia drugs market is divided into second-generation antipsychotics, third-generation antipsychotics, and others. The second-generation drug class is further segmented into latuda, risperdal, geodon, invega, seroquel, aristada, fanapt, saphris, zyprexa, and vraylar. The others segment is bifurcated into first-generation antipsychotics and generics. The second-generation antipsychotics segment is expected to grow at a considerable pace in the coming years as this drug type is widely used in the treatment of schizophrenia. The effectiveness of the drug in the treatment of the disease is the main factor for the segment growth. Meanwhile, the third-generation antipsychotics segment is projected to register a fast growth rate during forecast period attributed to the fast action and wide preference in combination therapy.

Schizophrenia Drugs Market classes

Injectable antipsychotic segment is projected to expand at a considerable CAGR

On the basis of treatments, the market is bifurcated into injectable and oral antipsychotics. The injectable antipsychotic segment is projected to expand at a considerable CAGR during the forecast period due to the advancement of the treatment method along with high efficacy rate and decreased chance for hospitalization. However, the oral antipsychotic segment is anticipated to grow at a substantial pace during the projected period attributed to the easy availability of the drugs and is considered to be the first-line treatment for the disease. Moreover, there is a huge number of new drug approvals in the pipeline.

North America is anticipated to constitute a key market share

In terms of regions, the global schizophrenia drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to constitute a key market share in the near furture due to the presence of a large number of patients in the region. Furthermore, the existing developed structure for medical care for early treatment, wide culture of early diagnosis, as well as initiatives taken by the governments in the region play major factors driving the regional market growth.

Schizophrenia Drugs Market region

However, Asia Pacific is a fast-growing region and the market growth of the region is expected to exhibit a healthy rate during the forecast period. The regional market growth is attributed to the increased interest by several governments’ healthcare policies, high spending in healthcare expenditure, and increased funding for new treatment technology.

Segments

Segments Covered in the Report

The global schizophrenia drugs market has been segmented on the basis of

Therapeutic Classes

  • Second-generation Antipsychotics
    • Risperdal
    • Invega
    • Zyprexa
    • Geodon
    • Seroquel
    • Latuda
    • Aristada
    • Fanapt
    • Saphris
    • Vraylar
  • Third-generation Antipsychotics
    • Abilify
  • Others
    • First-generation Antipsychotics
    • Generics

Treatments

  • Oral Antipsychotics
  • Injectable Antipsychotics

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Johnson & Johnson
  • Alkermes
  • Vanda Pharmaceuticals
  • Bristol-Myers Squibb and Company/Otsuka Pharmaceuticals
  • Eli Lilly
  • Sumitomo Dainippon Pharma
  • AstraZeneca
  • Pfizer
  • Allergan/Geodon Ritcher.

Competitive Landscape

Key players competing in the global schizophrenia drug market are Johnson & Johnson; Alkermes; Vanda Pharmaceuticals; Bristol-Myers Squibb and Company/Otsuka Pharmaceuticals; Eli Lilly; Sumitomo Dainippon Pharma; AstraZeneca; Pfizer; and Allergan/Geodon Ritcher.

Schizophrenia Drugs Market keyplayers

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Schizophrenia Drugs Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Schizophrenia Drugs Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Schizophrenia Drugs Market - Supply Chain
  4.5. Global Schizophrenia Drugs Market Forecast
     4.5.1. Schizophrenia Drugs Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Schizophrenia Drugs Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Schizophrenia Drugs Market Absolute $ Opportunity
5. Global Schizophrenia Drugs Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Schizophrenia Drugs Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Schizophrenia Drugs Demand Share Forecast, 2019-2026
6. North America Schizophrenia Drugs Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Schizophrenia Drugs Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Schizophrenia Drugs Demand Share Forecast, 2019-2026
7. Latin America Schizophrenia Drugs Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Schizophrenia Drugs Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Schizophrenia Drugs Demand Share Forecast, 2019-2026
8. Europe Schizophrenia Drugs Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Schizophrenia Drugs Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Schizophrenia Drugs Demand Share Forecast, 2019-2026
9. Asia Pacific Schizophrenia Drugs Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Schizophrenia Drugs Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Schizophrenia Drugs Demand Share Forecast, 2019-2026
10. Middle East & Africa Schizophrenia Drugs Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Schizophrenia Drugs Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Schizophrenia Drugs Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Schizophrenia Drugs Market: Market Share Analysis
  11.2. Schizophrenia Drugs Distributors and Customers
  11.3. Schizophrenia Drugs Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Johnson & Johnson
     11.4.2. Alkermes
     11.4.3. Vanda Pharmaceuticals
     11.4.4. Bristol-Myers Squibb and Company/Otsuka Pharmaceuticals
     11.4.5. Eli Lilly
     11.4.6. Sumitomo Dainippon Pharma
     11.4.7. AstraZeneca

Segments Covered in the Report

The global schizophrenia drugs market has been segmented on the basis of

Therapeutic Classes

  • Second-generation Antipsychotics
    • Risperdal
    • Invega
    • Zyprexa
    • Geodon
    • Seroquel
    • Latuda
    • Aristada
    • Fanapt
    • Saphris
    • Vraylar
  • Third-generation Antipsychotics
    • Abilify
  • Others
    • First-generation Antipsychotics
    • Generics

Treatments

  • Oral Antipsychotics
  • Injectable Antipsychotics

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Johnson & Johnson
  • Alkermes
  • Vanda Pharmaceuticals
  • Bristol-Myers Squibb and Company/Otsuka Pharmaceuticals
  • Eli Lilly
  • Sumitomo Dainippon Pharma
  • AstraZeneca
  • Pfizer
  • Allergan/Geodon Ritcher.

Key players competing in the global schizophrenia drug market are Johnson & Johnson; Alkermes; Vanda Pharmaceuticals; Bristol-Myers Squibb and Company/Otsuka Pharmaceuticals; Eli Lilly; Sumitomo Dainippon Pharma; AstraZeneca; Pfizer; and Allergan/Geodon Ritcher.

Schizophrenia Drugs Market keyplayers

Buy Report